Diamedica shares surge 10.24% intraday as major shareholder buys $7.63M in stock; company develops DM199 for preeclampsia and stroke.

miércoles, 10 de diciembre de 2025, 10:22 am ET1 min de lectura
DMAC--
DiaMedica Therapeutics surged 10.24% intraday as a major shareholder acquired 1.06 million shares at an average price of $7.19, totaling $7.63 million, with the transactions occurring from November 17 to 25 and disclosed on December 8. The company is a clinical-stage biopharma firm developing recombinant human tissue kallikrein-1 KLK1 protein DM199 for preeclampsia and acute ischemic stroke.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios